Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Lenvima

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,241Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer
    Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer

    29 Oct 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/merck-eisai-scrap-ambitions-keytruda-lenvima-pairing-liver-cancer-subtype-after-survival

    FIERCE PHARMA
    29 Oct 2025
    Share Share
    Keytruda and Lenvima Show Long-Term Survival Benefit
    Keytruda and Lenvima Show Long-Term Survival Benefit

    18 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251018972232/en/KEYTRUDA-pembrolizumab-Plus-LENVIMA-lenvatinib-Demonstrates-Durable-5-Year-Survival-Benefit-Versus-Chemotherapy-for-Patients-With-Advanced-Endometrial-Carcinoma-Following-One-Prior-Platinum-Based-Regimen

    BUSINESSWIRE
    18 Oct 2025
    Share Share
    Eisai to Present 5-Year KEYNOTE-775 Data at ESMO 2025
    Eisai to Present 5-Year KEYNOTE-775 Data at ESMO 2025

    02 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-highlights-breadth-of-oncology-research-at-esmo-2025-featuring-5-year-survival-data-from-study-309keynote-775-302573253.html

    PR NEWSWIRE
    02 Oct 2025
    Share Share
    Akeso Starts Global Cadonilimab Trial in Resistant Liver Cancer
    Akeso Starts Global Cadonilimab Trial in Resistant Liver Cancer

    15 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/akeso-announces-first-patient-dose-in-global-registrational-trial-of-cadonilimab-pd-1ctla-4-for-pd-1-treatment-resistant-hepatocellular-carcinoma-302555984.html

    PR NEWSWIRE
    15 Sep 2025
    Share Share
    ImmuneOncia Reveals Phase 1b Results for CD47 Antibody at ASCO
    ImmuneOncia Reveals Phase 1b Results for CD47 Antibody at ASCO

    02 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immuneoncia-announces-interim-results-from-phase-1b-clinical-trial-of-next-generation-cd47-antibody-imc-002-at-asco-2025-302470514.html

    PR NEWSWIRE
    02 Jun 2025
    Share Share
    Merck, Eisai combo misses survival goal in GI cancer trial
    Merck, Eisai combo misses survival goal in GI cancer trial

    25 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/merck-eisai-star-crossed-keytruda-lenvima-combo-misses-survival-goal-gi-cancer-trial

    FIERCE PHARMA
    25 Jan 2025
    Share Share